EVAX Evaxion
Price Chart
Executive Summary
Evaxion announced new data from a collaboration with Duke University showing its AI-Immunology™ platform can identify endogenous retrovirus (ERV)-derived antigens for use in personalized vaccines for glioblastoma, a deadly brain cancer with limited treatment options. The findings, to be presented at AACR 2026, demonstrate a novel antigen source that could improve vaccine efficacy in low mutational burden cancers.
Actionable Insight
Traders should monitor for follow-up announcements post-AACR presentation, including potential partnership talks or research expansions. This proof-of-concept strengthens Evaxion’s platform narrative, which may re-rate the stock if commercial interest materializes.
Key Facts
- AI-Immunology™ platform identified ERV-derived antigens in glioblastoma tumor samples, a novel target source absent in normal tissue.
- Data shows feasibility of including both ERV antigens and neoantigens in personalized vaccines for most glioblastoma patients.
- Immunologic responses to ERV antigens were experimentally confirmed, supporting clinical potential.
- Results to be presented at AACR Annual Meeting on April 22, 2026, increasing scientific visibility.
- Glioblastoma has low mutational burden and few neoantigens, making this new antigen source highly significant.
Financial Impact
Non-dilutive scientific validation with potential to increase partnership and licensing interest; no immediate revenue impact but enhances platform valuation.
Risk Factors
- Clinical application remains preclinical; no guarantee of therapeutic success in humans.
- High market expectations could lead to sell-off if AACR data underwhelms or lacks robustness.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276449 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
28d ago
|
6-K
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.63 (−12.95%) |
|
May 12, 2026
28d ago
|
Press Release
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.63 (−12.95%) |
|
May 7, 2026
4w ago
|
6-K
| $4.07 $4.16 | ▲ +2.21% | ▲ +0.71% | $3.63 (−10.81%) |
|
May 4, 2026
5w ago
|
Press Release
| $4.57 $4.23 | ▼ −7.55% | ▼ −10.49% | $3.63 (−20.57%) |
|
Apr 27, 2026
6w ago
|
6-K
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.63 (−13.16%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.63 (−13.16%) |
|
Apr 22, 2026
6w ago
|
6-K
| $4.27 $4.27 | · 0.00% | ▼ −0.05% | $3.63 (−14.99%) |
|
Apr 17, 2026
7w ago
|
6-K
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.63 (−18.43%) |
|
Apr 17, 2026
7w ago
|
6-K
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.63 (−18.43%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.63 (−18.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access